Michael Shine

Form D signer

Michael Shine

Chief Executive Officer of Issuer at NK-One Therapeutics

Form D signer

Capital raised by NK-One Therapeutics

$290K+$290K latest round

1 Form D filing · first filed Mar 2026 · Wayne, PA

CURRENT ROLE: Chief Executive Officer of Issuer
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: 2026
30D INTEREST: —

Career

1 company on file · founded 2026

NK-One TherapeuticsBiotech · Wayne, PAsince 2026

Chief Executive Officer of Issuer

Signatory on NK-One Therapeutics's Form D filings · $290K raised across 1

Company filings

via EDGAR · Form D for NK-One Therapeutics1

DateCompanyFormAmountRole on filing

Mar 4, 2026NK-One TherapeuticsForm D+$290KChief Executive Officer of Issuer

Form DMar 4, 2026 · NK-One Therapeutics+$290Kas Chief Executive Officer of Issuer

Overview

Last filing Mar 4, 2026

Michael Shine is on file as Chief Executive Officer of Issuer at NK-One Therapeutics in Wayne, PA. NK-One Therapeutics has 1 Form D filing on record, $290K raised in total. Michael Shine appears as a signatory on the company's filings.

Teammates

NK-One Therapeutics · 1

Marco PappagalloDirector

Products

NK-One Therapeutics · 1

SP-SAP (Substance P-Saporin)Drug candidate

A substance P-saporin conjugate delivered intrathecally that selectively disables neurokinin-1 receptor-expressing neurons in the spinal dorsal horn to halt intractable cancer pain.